Recent advancements in gene therapy have brought new hope for patients with Zellweger Spectrum Disorder (ZSD), particularly concerning the progressive vision loss that characterizes the condition. A groundbreaking study evaluated the efficacy of an adeno-associated virus (AAV) vector, specifically AAV8.CMV.HsPEX1.HA, in a mouse model bearing the PEX1-Gly844Asp mutation, which is the murine equivalent of the most common human mutation causing mild ZSD.
Zellweger Spectrum Disorder is a rare, autosomal recessive condition caused by mutations in any of the 13 PEX genes responsible for peroxisome assembly and function. The PEX1 gene is the most commonly affected, accounting for nearly 70% of all ZSD cases. Peroxisomes are vital cellular organelles involved in lipid metabolism, and their dysfunction leads to the accumulation of toxic very-long-chain fatty acids (VLCFAs) and a deficiency in essential plasmalogens. This metabolic imbalance causes widespread systemic issues, with the retina being particularly vulnerable. Most patients with milder forms of ZSD develop progressive retinal degeneration, leading to severe visual impairment or blindness.
In this proof-of-concept study, researchers aimed to determine if localized gene augmentation could restore peroxisomal function in the retina and halt or reverse vision loss. They administered the therapeutic AAV vector via subretinal injection to mice at early (5 weeks old) and later (9 weeks old) stages of retinopathy. The results were highly encouraging. The HsPEX1 protein was successfully expressed in the retina without causing any gross histological side effects or inflammation, indicating that the viral vector was well-tolerated by the ocular tissues.
More importantly, the treatment partially normalized peroxisomal metabolic functions. Researchers observed improved levels of retinal C26:0 lysophosphatidylcholine, a key biomarker for peroxisomal activity. Functional assessments using full-field flash electroretinogram (ffERG) demonstrated significant improvements in visual response. At eight weeks post-injection, the treated eyes showed a twofold improvement in retinal response compared to control eyes that received a sham injection. This improvement was not just temporary; it was sustained over the long term. Treated eyes continued to exhibit double the ffERG response of control eyes even when the mice reached 32 weeks of age. Additionally, behavioral tests assessing the optomotor reflex showed a positive trend toward improved visual acuity in the treated mice.
The significance of this research cannot be overstated. Progressive vision loss, including retinitis pigmentosa and macular atrophy, profoundly impacts the quality of life for individuals with milder ZSD, affecting their communication, mobility, and autonomy. By demonstrating that AAV-mediated gene augmentation can effectively restore localized peroxisomal function and preserve retinal integrity in a mammalian model, this study paves the way for future clinical trials in humans. If successful, such treatments could prevent or slow retinal deterioration, offering a targeted therapy for a symptom that currently has no cure.
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Genetic testing and clinical management should be performed by qualified healthcare professionals.